Johnson & Johnson (NYSE:JNJ) misses quarterly revenue expectations as stelara sales disappoint

Grafa
04-16

Johnson & Johnson (NYSE:JNJ) reported lower-than-expected quarterly revenue as sales from its leading psoriasis treatment, Stelara, underperformed amidst looming market competition.

The pharmaceutical giant saw its shares drop nearly 2% in premarket trading due to flat sales of Stelara, which amounted to $2.45 billion for the first quarter, falling short of the projected $2.6 billion.

Despite the setback with Stelara, whose key patent expired last year, J&J has managed to delay the entry of biosimilar competitors in the U.S. until 2025.

This strategic move is expected to bolster the drug’s contributions to J&J’s revenue through 2024 and 2025.

On a brighter note, J&J’s blood cancer therapy Darzalex performed well, with sales increasing by 19% to $2.69 billion, aligning closely with expectations.

Darzalex continues to be a strong performer, projected to generate over $11 billion in annual sales.

Overall, J&J earned $2.71 per share on an adjusted basis in the first quarter, surpassing the analyst estimates of $2.64.

Meanwhile, the company's total revenue was slightly below expectations at $21.38 billion compared to the forecasted $21.40 billion.

Looking ahead, Johnson & Johnson has adjusted its 2024 operating profit outlook to between $10.60 and $10.75 per share, refining the lower end of its previous forecast.

Claim Now

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（3）

  • Top
  • Latest
  • AfraSimon
    ·04-16
    Looks like JNJ is still holding strong despite the market competition.
    Reply
    Report
  • Tom Chow
    ·04-17
    good
    Reply
    Report
  • KSR
    ·04-17
    👍
    Reply
    Report